A search was conducted in a prospectively maintained LT database between Jan, 2000 and Dec, 2018. Among 332 patients undergoing LT for HCC, 81 patients without bridging procedures, 139 patients treated with other locoregional therapy (radiofrequency ablation (RFA), TACE+RFA and percutaneous ethanol injection (PEI)) and 6 patients receiving hepatic resection prior to LT were excluded. We also excluded 40 patients without pre- and/or post-TACE imaging. The final study population consisted of 66 patients treated only with TACE. Diagnosis of HCC was made on histologic or radiologic criteria according to published guidelines [16] and confirmed on explant histopathology analysis. Percutaneous biopsy for diagnosis of HCC was not routinely performed.
In line with our center’s policy, TACE was performed in patients with a greater tumor burden than Milan Criteria at initial imaging, or in patients within Milan Criteria and with an expected more than 2 months of waiting time. Patients were excluded from TACE if they had decompensated cirrhosis (Child-Pugh B, score >8), severely reduced portal vein flow, extensive tumor with massive replacement of both lobes, renal insufficiency (creatinine ≥2 mg/dL or creatinine clearance ≤30 mL/min) and untreatable arterio-venous fistula [17]. In all cases data from both the initial CT investigation and the last CT scan after TACE before LT if available were evaluated.
CT Technique and image evaluation
The pre- and post TACE multiphasic contrast enhanced studies of the enrolled subjects were performed on multidetector computed tomography (MDCT) scanners (ranging from 8 to 64 rows of detectors), with 0.6- to 1.5-mm collimation, 3-mm slice interval and 3- to 5-mm slice thickness. Patients were scanned before and after the intravenous administration of iodine contrast media in the arterial phase, portal-venous phase and equilibrium phase. The studies were retrospectively reviewed on commercially available workstations (MV1000, Siemens Healthcare, and IMPAX, Agfa Healthcare) simultaneously by two expert abdominal radiologists, and unaware of the explant histopathology findings.
The largest diameter of the enhancing portion of the lesions concerning for HCC on pre-TACE CT scan was measured on the imaging phase in which the lesion was best seen, and only lesions greater than or equal to 1-cm were included in the study. The HCC attenuation in each phase was classified as hyper-attenuation, iso-attenuation or hypo-attenuation compared with the surrounding liver parenchyma. A lesion with heterogeneous enhancement was regarded as hyper-attenuating when most of it was enhanced during the arterial phase compared with the pre-contrast phase. Hyper-attenuation on the arterial phase followed by washout in the portal or equilibrium phase was defined as “typical enhancement”. A hypo-attenuated area with no change in the degree of attenuation during the dynamic phase was defined as necrosis. The shape of the tumor margin was categorized into three subgroups: smooth; lobulated or infiltrative. Capsule appearance means a rim of hyper-enhancement in portal, delayed, or transitional phase, which is unequivocally thicker than fibrotic tissue around background nodules [18].
HCC lesions were classified in three major categories based on their pattern of enhancement and margins, as follows: Type A: Well-defined (or circumscribed) tumors with arterial phase hyper enhancement (relative to the background liver parenchyma) and portal-venous or equilibrium phase wash-out; Type B: Well-defined (or circumscribed) tumors with arterial phase iso- or hypo enhancement (relative to the background liver parenchyma) and portal-venous or equilibrium phase wash-out; Type C: Poorly defined (or infiltrative) tumors, irrespective of their enhancement pattern.
CT follow-up was performed 1 month after TACE and at least every 3 months until LT. The post-TACE CT scan images performed prior to the liver transplant were subsequently reviewed in the same session and compared side-by-side with the pre-TACE CT scan, in order to assess the treatment response. The responses to TACE were categorized according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) [19] as follows: complete response (CR), disappearance of any intratumoral arterial enhancement; partial response (PR), ≥30% decrease in the diameter of the viable (enhancement in the arterial phase) portion of a target lesion (taking the baseline diameter of the target lesion as a reference); progressive disease (PD), ≥20% increase in the diameter of the viable portion of a target lesion (taking as reference the baseline diameter of the target lesion); and stable disease (SD), any cases not categorized as PR or PD.
TACE protocol
TACE was performed after patients provided written informed consent. A 5-F catheters or 3-F coaxial microcatheters was inserted into the common femoral artery and angiographic survey of the celiac and superior mesenteric arteries was performed. Common hepatic angiography was performed to visualize the tumor blood supply, and then a microcatheter was selectively inserted into the artery feeding the tumor. A mixture of chemotherapeutic agents and Lipiodol was infused into the supplying arteries. Under fluoroscopic guidance, the vessels were subsequently embolized with Gelfoam until complete flow stagnation was achieved. The interventional radiologist chose the type and amount of the chemotherapeutic and embolic agents at the time of the procedure. The amount of administered mixture was decided on the basis of number, location and diameter of lesions. If residual viable tumor foci remained in the liver or new tumors emerged but the patients maintained adequate hepatic function and reserve, TACE was repeated at 6 to 8 week intervals.
Histopathology:
After transplantation, all explants were submitted for review by an experienced hepatopathologist. Native livers were serially sectioned, grossly examined, and fixed in formalin. Representative sections of the non-lesional liver of all lobes were subsequently embedded in paraffin. The size, number, location, and gross characteristics of all lesions were recorded. The degree of tumor differentiation (well, moderate, or poor) was graded according to Edmondson criteria. Presence of lymphovascular invasion was described. Tumors that demonstrated heterogeneous differentiation were grouped according to the worst histologic grade evident within the tumor. Viable tumor was defined by histology alone as neoplastic cells with maintenance of cytoplasmic and nuclear morphology, in contrast to the necrotic tumor, which lost these features and in many cases showed coagulative type necrosis. The percentage of tumor necrosis was calculated as the ratio of the necrotic tissue to the entire tumor area. A necrosis of 100% was assumed to indicate complete necrosis. Tumor necrosis between 90%-99% was defined as near-complete necrosis.
Statistical Analysis:
Continuous variables were expressed as means and standard deviations, medians and ranges, or both. Categorical variables were reported as numbers and percentages. Pearson’s chi-square tests or Fisher’s exact tests was performed to evaluate categorical variables and the Student’s t-test for continuous data. Continuous variables were transformed into binary variables and the cutoffs were chosen according to previous studies. After univariate analysis, only variables that emerged as significant were used in the multivariate analysis using Cox’s proportional hazard model. Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values and accuracy of CT in the detection of 100% necrosis were calculated. A two-tailed P-value of <0.05 was considered to be statistically significant. Statistical analyses were performed with SPSS 22.0 (SPSS, Inc., Chicago, IL) for Windows.